-
effectivehealthcare.ahrq.gov/sites/default/files/ahrq_community_forum_webinar_bonoff.pdf
January 01, 2000 - learning: lectures, study group sessions, case studies, role play,
homework, personal action plan, and continuing … care courses
– Annual Advocacy Training Conference
– Team Leader training
– Emerging Leaders
– Continuing … Continuing Education, mentoring
Types of Project LEAD Courses
• Project LEAD® Institute- an … learning environment
for weakest to learn most, risk zone theory, graduate
action plan
• Offer continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/bonoff-text.pdf
January 01, 2000 - learning: lectures, study group sessions, case studies, role play, homework,
personal action plan, and continuing … § Emerging Leaders
§ Continuing … safe learning environment for weakest to learn
most, risk zone theory, graduate action plan
§ Offer continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0352_09-22-2010.pdf
January 01, 2010 - pregnancy; and (2)
Women who have mild, moderate, or severe depression and are pregnant
Intervention(s): Continuing … with depression, what
are the comparative harms or benefits for both fetus/infant and the mother of
continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0094_04-09-2009.pdf
January 01, 2009 - e.g., sleep disorder, dietary and/or nutritional deficiencies,
GI conditions, and allergies) versus continuing … communicative speech in response
to early behavioral intervention, what is the comparative effectiveness of
continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/multiple-sclerosis_executive.pdf
April 01, 2015 - We
looked for evidence that directly assessed discontinuing
versus continuing DMT and also evidence … for long-
term (more than 3 years) benefits and harms for either
continuing or discontinuing, since … What is the evidence for benefits for continuing versus
discontinuing treatment?
b. … We
therefore turned to literature examining benefits for
continuing DMT long term. … No literature directly compared continuing versus
discontinuing DMT in comparable populations.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
September 30, 2015 - months followup
C: Control (no opioid), new users (n=18,824), dose NA, 24.4 months followup
D: Tramadol, continuing … users (n=7,075), dose NR, 28.4 months followup
E: Other opioids, continuing users (n=7,238), dose NR … , 28.4 months followup
F: Control (no opioid), continuing users (n=7,075), dose NA Age, mean ranges:
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-fracture-prevention-evidence-summary.pdf
April 01, 2019 - • Continuing bisphosphonates after 3–5 years
versus discontinuation reduces some measures of
vertebral … We
found no evidence about possible modifiers of the
effect of continuing any other osteoporosis drug … Skeletal effects of
raloxifene after 8 years: results from the continuing
outcomes relevant to Evista … Continuing outcomes relevant to Evista: breast cancer
incidence in postmenopausal osteoporotic women … Effects of
continuing or stopping alendronate after 5 years of
treatment: the Fracture Intervention
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-2.xlsx
September 30, 2015 - months followup
C: Control (no opioid), new users (n=18,824), dose NA, 24.4 months followup
D: Tramadol, continuing … users (n=7,075), dose NR, 28.4 months followup
E: Other opioids, continuing users (n=7,238), dose NR … , 28.4 months followup
F: Control (no opioid), continuing users (n=7,075), dose NA Age, mean ranges:
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-pregnant-women-or-women-recieving-preconception-care-with-depression-what-are-the-comparative-harms-or-benefits-for-both-fetusinfant-and-the-mother-of-continuing-treatment-with-anti-depressants
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/antibiotics-respiratory-infection_clinician.pdf
March 01, 2016 - the rate of
adverse consequences, including days of limited activity
or missed work and rates of continuing … ���
Adverse consequences — No difference in number of days of limited activity or missed work or continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/incident-user-design_research.pdf
May 01, 2012 - How well can non-randomized studies approximate
randomized controlled trials if they follow continuing … what is
the theoretical motivation to prefer the incident user design over other choices that enroll
continuing … because patients (or their employers) discontinue insurance coverage with one
health plan and the continuing … only refer to the second drug
(possibly an augmentation); it would be acceptable for patients to have continuing … first-line, second-line, and third-line therapy defined as incident users and
compare their findings with continuing
-
effectivehealthcare.ahrq.gov/about/former
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-pregnancy-postpartum_disposition-comments.pdf
July 08, 2014 - population was intended to be women with a
episode of depression beginning during pregnancy, rather than a
continuing … Some are continuing treatment
with an antidepressant (in remission) depression and some are not. … being on
women who develop depression during pregnancy or the
pp period, rather than those with a continuing … Some included information on depression history, and a few were
clear that the episode was a continuing … new episode (not necessarily the first)
of depression during pregnancy or postpartum, rather than a
continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pdf/epc-maternal-health-grand-rounds-slides.pptx
January 01, 2023 - Lisa Simpson, M.B., B.Ch., M.P.H., FAAP
President and Chief Executive Officer – AcademyHealth
Continuing … implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/autism-update_clinician.pdf
September 01, 2014 - Future Research Needs
� Continuing improvements in methodological rigor in the
field, including:
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
September 30, 2015 - months followup
C: Control (no opioid), new users (n=18,824), dose NA, 24.4 months followup
D: Tramadol, continuing … users (n=7,075), dose NR, 28.4 months followup
E: Other opioids, continuing users (n=7,238), dose NR … , 28.4 months followup
F: Control (no opioid), continuing users (n=7,075), dose NA Age, mean ranges:
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pdf/epc-pain-management-grand-rounds-slides.pptx
March 01, 2022 - , M.B., B.Ch., M.P.H., FAAP
President and Chief Executive Officer – AcademyHealth
Facilitators
Continuing … implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/treatment-resistant-depression_research-protocol.pdf
December 09, 2009 - the effects of
a single treatment intervention (e.g., after medication failure, switching to ECT vs. continuing … medications) or of a treatment combination (e.g., after medication failure, adding ECT to
medications vs. continuing
-
effectivehealthcare.ahrq.gov/sites/default/files/oct_13_webinar_transript_10-13-11.pdf
October 13, 2011 - Where are they going to take it and to support that
continuing education? … And I will now
continue the description of how we built this program and
how it’s continuing … what each student is going to do with that
learning to support their advocacy career and offer
continuing … And they
also have to be willing to accept the continuing commitment
to refine and improve the course … It’s a continuing and an impressive
faculty commitment.
-
effectivehealthcare.ahrq.gov/sites/default/files/module_ii1.ppt
June 01, 2011 - The Journal of Continuing Education in the Health Professions, 26: 13-24.
Hashagen, S. (2002). … Journal of Continuing Education in the Health Professions, 28(2): 67-72.